9 results
8-K
EX-99.1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
28 Jan 22
Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides
8:03am
through an integrated offering. Further, MyChem will help accelerate Maravai’s innovation capabilities with additional R&D resources.
“MyChem’s … for therapeutics and vaccine applications, expected benefits to customers, acceleration of R&D capabilities, plans to scale the acceleration and accelerate growth
8-K
EX-99.1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
23 Feb 22
Maravai Lifesciences Reports Fourth Quarter and Full Year 2021 Financial Results and Updates 2022 Financial Guidance
4:08pm
ultra-pure nucleotides; and
Conducted inaugural Investor R&D Day.
"Maravai remains on an exciting trajectory with 2022 revenues expected to grow 15 … investments in R&D across the Company, to invest in our capacity and people, and to capitalize on smart business development opportunities.”
Revenue
8-K
EX-99.1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
3 Oct 22
Maravai LifeSciences Announces CEO Leadership Transition
4:07pm
, managing complex R&D programs, driving global commercial initiatives, and executing strategic acquisitions. Additionally, he has a stellar reputation
8-K
EX-99.1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
7 Nov 23
Maravai Lifesciences Reports Third Quarter 2023 Financial Results
4:11pm
policies that will spur future mRNA breakthroughs.
Awards and Recognitions:
Cygnus Technologies received a 2023 R&D 100 Award from R&D World
8-K
EX-99.1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
10 Aug 21
Maravai Lifesciences Reports Second Quarter Financial Results and Updates 2021 Financial Guidance
4:18pm
will significantly increase cold storage capacity, provide a Mass Spectrometry Center of Excellence and specialized cell culture facilities, among other R&D, laboratory
8-K
EX-99.1
emzwxhq5idykgi36
5 May 22
Maravai Lifesciences Reports First Quarter 2022 Financial Results
12:00am
10-K
jtp4pu9rs7ju0g
22 Mar 21
Annual report
4:22pm
- Prev
- 1
- Next